TransCode Therapeutics Statistics
Total Valuation
RNAZ has a market cap or net worth of $28.78 million. The enterprise value is $21.05 million.
| Market Cap | 28.78M |
| Enterprise Value | 21.05M |
Important Dates
The last earnings date was Friday, August 14, 2026, after market close.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RNAZ has 16.93 million shares outstanding. The number of shares has increased by 246.69% in one year.
| Current Share Class | 16.93M |
| Shares Outstanding | 16.93M |
| Shares Change (YoY) | +246.69% |
| Shares Change (QoQ) | +4.39% |
| Owned by Insiders (%) | 2.03% |
| Owned by Institutions (%) | 0.52% |
| Float | 2.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.21 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.97, with a Debt / Equity ratio of 0.00.
| Current Ratio | 1.97 |
| Quick Ratio | 1.55 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3,900.25 |
Financial Efficiency
Return on equity (ROE) is -59.28% and return on invested capital (ROIC) is -21.84%.
| Return on Equity (ROE) | -59.28% |
| Return on Assets (ROA) | -19.90% |
| Return on Invested Capital (ROIC) | -21.84% |
| Return on Capital Employed (ROCE) | -17.42% |
| Weighted Average Cost of Capital (WACC) | 10.48% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.86M |
| Employee Count | 12 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, RNAZ has paid $457,677 in taxes.
| Income Tax | 457,677 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.33% in the last 52 weeks. The beta is 1.17, so RNAZ's price volatility has been higher than the market average.
| Beta (5Y) | 1.17 |
| 52-Week Price Change | -83.33% |
| 50-Day Moving Average | 3.74 |
| 200-Day Moving Average | 7.00 |
| Relative Strength Index (RSI) | 34.45 |
| Average Volume (20 Days) | 74,954 |
Short Selling Information
The latest short interest is 45,978, so 0.27% of the outstanding shares have been sold short.
| Short Interest | 45,978 |
| Short Previous Month | 30,910 |
| Short % of Shares Out | 0.27% |
| Short % of Float | 2.14% |
| Short Ratio (days to cover) | 0.61 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -25.36M |
| Pretax Income | -42.38M |
| Net Income | -46.28M |
| EBITDA | -25.26M |
| EBIT | -25.36M |
| Earnings Per Share (EPS) | -$51.08 |
Balance Sheet
The company has $8.38 million in cash and $652,411 in debt, with a net cash position of $7.73 million or $0.46 per share.
| Cash & Cash Equivalents | 8.38M |
| Total Debt | 652,411 |
| Net Cash | 7.73M |
| Net Cash Per Share | $0.46 |
| Equity (Book Value) | 138.36M |
| Book Value Per Share | -27.38 |
| Working Capital | 5.24M |
Cash Flow
In the last 12 months, operating cash flow was -$22.61 million and capital expenditures -$6,660, giving a free cash flow of -$22.61 million.
| Operating Cash Flow | -22.61M |
| Capital Expenditures | -6,660 |
| Depreciation & Amortization | 97,434 |
| Net Borrowing | 950,000 |
| Free Cash Flow | -22.61M |
| FCF Per Share | -$1.34 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RNAZ does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -246.69% |
| Shareholder Yield | -246.69% |
| Earnings Yield | -160.80% |
| FCF Yield | -78.56% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 15, 2025. It was a reverse split with a ratio of 1:28.
| Last Split Date | May 15, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:28 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |